Medytox Solutions (MMMS) 4.5000 $MMMS
CollabRx announces non-binding letter of intent for proposed business combination with Medytox Solutions
M2 - Fri Jan 23, 8:03PM CST
Medical information company CollabRx (NasdaqCM:CLRX) reported on Thursday the execution of a non-binding letter of intent to negotiate a potential business combination with Medytox Solutions (OTCBB:MMMS).
CLRX: 1.84 (+0.04)
CollabRx and Medytox Solutions Sign Non-Binding Letter of Intent for Possible Business Combination
Marketwired - Thu Jan 22, 5:30AM CST
CollabRx, Inc. (NASDAQ: CLRX) and Medytox Solutions, Inc. (OTCQB: MMMS) ("Medytox"
have entered into a non-binding letter of intent to negotiate a potential business combination. Also, CollabRx and Medytox announced that they have entered into agreements that would secure funding needed by CollabRx to continue to operate while the parties negotiate a potential business combination. The potential business combination is subject to, among other things, due diligence, the execution of a definitive agreement, necessary Board of Directors and stockholder approvals and other customary conditions.
CLRX: 1.84 (+0.04)
Medytox Diagnostics' International Technologies awarded the New York State Department's Health Clinical Laboratory permit
M2 - Thu Jan 08, 4:53AM CST
Medytox Diagnostics stated on Wednesday that its New Jersey-based laboratory, International Technologies, has been certified with a Clinical Laboratory Permit by the New York State Department of Health.
Medytox Diagnostics Awarded License to Begin Lab Testing in New York State
Marketwired - Wed Jan 07, 10:06AM CST
The New York State Department of Health awarded Medytox Diagnostics, Inc.'s New Jersey-based laboratory, International Technologies, LLC, with a Clinical Laboratory Permit that allows the lab to begin servicing clients throughout New York State with a full continuum of laboratory services, including sophisticated drug screening. Medytox Diagnostics, a subsidiary of Medytox Solutions, Inc. (OTCBB: MMMS), has carved a niche serving the drug testing needs of substance abuse facilities and pain management practices at its New Jersey lab and its network of laboratories nationwide.
CORRECTION - Medytox Billing Subsidiary Expands Patient Relations Department
Marketwired - Tue Dec 30, 9:00AM CST
In the news release, "Medytox Billing Subsidiary Expands Patient Relations Department," issued Wednesday, December 24, 2014 by Medytox Solutions, Inc. (OTCBB: MMMS), we are advised by the company that the fourth paragraph should read "William DePond, M.D., COO of Medytox Diagnostics, Inc., and CEO of Medytox-owned laboratories" rather than "William DePond, M.D., COO of Medytox Solutions, Inc., and CEO of Medytox laboratories" as originally issued. Complete corrected text follows.
Medytox Billing Subsidiary Expands Patient Relations Department
Marketwired - Wed Dec 24, 9:30AM CST
Medical Billing Choices, Inc., a subsidiary of Medytox Solutions, Inc., has created a new Patient Relations department to assist the growing number of patients served through Medytox-owned laboratories with the patient responsibility portion of claims generated for services. Medytox's network of laboratories provides a full continuum of laboratory and clinical testing services, including sophisticated drug screening, on behalf of physicians and facilities nationwide.
Fast-Growing Chain of Labs, Medytox Diagnostics, Announces CEO of Laboratories
Marketwired - Wed Dec 17, 10:21AM CST
Medytox Diagnostics, Inc., which owns and operates half a dozen clinical laboratories throughout the U.S., announced today it named William DePond, M.D., CEO of Medytox laboratories. In his role, Dr. DePond will oversee the company's expanding network of toxicology labs that specialize in drug screening and analysis for substance abuse facilities and the ongoing drug screening required for patients of pain management physicians.
Florida-Based Health Technology Company Hires Specialized PR and Marketing Firm
Marketwired - Wed Nov 19, 2:34PM CST
The Weinbach Group, a marketing communications firm with expertise in healthcare-related public relations and advertising, announced today that Medytox Solutions, Inc. (OTCBB: MMMS) selected the Miami public relations firm to build recognition for the West Palm Beach-based health technology company. Medytox, which has recently completed a number of strategic acquisitions, anticipates continued M&A activity into 2015. It will utilize The Weinbach Group to raise visibility among prospective targets for acquisition, capital sources, and industry decision makers who use services provided by Medytox' family of companies.
Electronic Health Records Developer, Medical Mime, Launches System for Substance Abuse Treatment Centers
Marketwired - Thu Nov 06, 10:44AM CST
Psychiatrists, psychologists, social workers, and other mental health professionals finally have an electronic health record (EHR) system created for their specific practice environments. Healthcare technology company, Medical Mime, announced today the introduction of a new EHR system tailored to therapists working at drug and alcohol treatment centers -- one of the markets Medical Mime's parent company, Medytox Solutions, Inc. (OTCBB: MMMS), serves. The new system was developed to address the wide range of clinical professionals who treat patients with chemical dependencies, many of whom have never used an EHR system before.
Laboratory and Health Technology Co., Medytox Solutions, Inc., Names Seamus Lagan New CEO
Marketwired - Wed Oct 29, 10:00AM CDT
Medytox Solutions, Inc. (OTCBB: MMMS), a diversified healthcare company that owns and operates lab and health IT companies, announced today it named Seamus Lagan as CEO. He is a longtime consultant to private companies in the United States and abroad and previously served as CEO for three of Medytox's subsidiaries: Medytox Marketing and Sales, Inc., Medytox Diagnostics, Inc., and Medytox Information and Technology, Inc. In his expanded role, Mr. Lagan will concentrate on Medytox's national growth, increasing the company's offerings, identifying businesses for potential acquisition and investment, and growing Medytox's management team. In addition, he will continue to raise capital for the company.
Medytox Solutions posts better income from operations of USD5.8m for 2014 quarter
M2 - Tue Aug 19, 11:09AM CDT
Clinical laboratory Medytox Solutions (OTC BB:MMMS) stated on Monday its income from operations of approximately USD5.8m for the three-month period ended 30 June 2014.
CollabRx announces non-binding letter of intent for proposed business combination with Medytox Solutions
M2 - Fri Jan 23, 8:03PM CST
Medical information company CollabRx (NasdaqCM:CLRX) reported on Thursday the execution of a non-binding letter of intent to negotiate a potential business combination with Medytox Solutions (OTCBB:MMMS).
CLRX: 1.84 (+0.04)
CollabRx and Medytox Solutions Sign Non-Binding Letter of Intent for Possible Business Combination
Marketwired - Thu Jan 22, 5:30AM CST
CollabRx, Inc. (NASDAQ: CLRX) and Medytox Solutions, Inc. (OTCQB: MMMS) ("Medytox"
have entered into a non-binding letter of intent to negotiate a potential business combination. Also, CollabRx and Medytox announced that they have entered into agreements that would secure funding needed by CollabRx to continue to operate while the parties negotiate a potential business combination. The potential business combination is subject to, among other things, due diligence, the execution of a definitive agreement, necessary Board of Directors and stockholder approvals and other customary conditions. CLRX: 1.84 (+0.04)
Medytox Diagnostics' International Technologies awarded the New York State Department's Health Clinical Laboratory permit
M2 - Thu Jan 08, 4:53AM CST
Medytox Diagnostics stated on Wednesday that its New Jersey-based laboratory, International Technologies, has been certified with a Clinical Laboratory Permit by the New York State Department of Health.
Medytox Diagnostics Awarded License to Begin Lab Testing in New York State
Marketwired - Wed Jan 07, 10:06AM CST
The New York State Department of Health awarded Medytox Diagnostics, Inc.'s New Jersey-based laboratory, International Technologies, LLC, with a Clinical Laboratory Permit that allows the lab to begin servicing clients throughout New York State with a full continuum of laboratory services, including sophisticated drug screening. Medytox Diagnostics, a subsidiary of Medytox Solutions, Inc. (OTCBB: MMMS), has carved a niche serving the drug testing needs of substance abuse facilities and pain management practices at its New Jersey lab and its network of laboratories nationwide.
CORRECTION - Medytox Billing Subsidiary Expands Patient Relations Department
Marketwired - Tue Dec 30, 9:00AM CST
In the news release, "Medytox Billing Subsidiary Expands Patient Relations Department," issued Wednesday, December 24, 2014 by Medytox Solutions, Inc. (OTCBB: MMMS), we are advised by the company that the fourth paragraph should read "William DePond, M.D., COO of Medytox Diagnostics, Inc., and CEO of Medytox-owned laboratories" rather than "William DePond, M.D., COO of Medytox Solutions, Inc., and CEO of Medytox laboratories" as originally issued. Complete corrected text follows.
Medytox Billing Subsidiary Expands Patient Relations Department
Marketwired - Wed Dec 24, 9:30AM CST
Medical Billing Choices, Inc., a subsidiary of Medytox Solutions, Inc., has created a new Patient Relations department to assist the growing number of patients served through Medytox-owned laboratories with the patient responsibility portion of claims generated for services. Medytox's network of laboratories provides a full continuum of laboratory and clinical testing services, including sophisticated drug screening, on behalf of physicians and facilities nationwide.
Fast-Growing Chain of Labs, Medytox Diagnostics, Announces CEO of Laboratories
Marketwired - Wed Dec 17, 10:21AM CST
Medytox Diagnostics, Inc., which owns and operates half a dozen clinical laboratories throughout the U.S., announced today it named William DePond, M.D., CEO of Medytox laboratories. In his role, Dr. DePond will oversee the company's expanding network of toxicology labs that specialize in drug screening and analysis for substance abuse facilities and the ongoing drug screening required for patients of pain management physicians.
Florida-Based Health Technology Company Hires Specialized PR and Marketing Firm
Marketwired - Wed Nov 19, 2:34PM CST
The Weinbach Group, a marketing communications firm with expertise in healthcare-related public relations and advertising, announced today that Medytox Solutions, Inc. (OTCBB: MMMS) selected the Miami public relations firm to build recognition for the West Palm Beach-based health technology company. Medytox, which has recently completed a number of strategic acquisitions, anticipates continued M&A activity into 2015. It will utilize The Weinbach Group to raise visibility among prospective targets for acquisition, capital sources, and industry decision makers who use services provided by Medytox' family of companies.
Electronic Health Records Developer, Medical Mime, Launches System for Substance Abuse Treatment Centers
Marketwired - Thu Nov 06, 10:44AM CST
Psychiatrists, psychologists, social workers, and other mental health professionals finally have an electronic health record (EHR) system created for their specific practice environments. Healthcare technology company, Medical Mime, announced today the introduction of a new EHR system tailored to therapists working at drug and alcohol treatment centers -- one of the markets Medical Mime's parent company, Medytox Solutions, Inc. (OTCBB: MMMS), serves. The new system was developed to address the wide range of clinical professionals who treat patients with chemical dependencies, many of whom have never used an EHR system before.
Laboratory and Health Technology Co., Medytox Solutions, Inc., Names Seamus Lagan New CEO
Marketwired - Wed Oct 29, 10:00AM CDT
Medytox Solutions, Inc. (OTCBB: MMMS), a diversified healthcare company that owns and operates lab and health IT companies, announced today it named Seamus Lagan as CEO. He is a longtime consultant to private companies in the United States and abroad and previously served as CEO for three of Medytox's subsidiaries: Medytox Marketing and Sales, Inc., Medytox Diagnostics, Inc., and Medytox Information and Technology, Inc. In his expanded role, Mr. Lagan will concentrate on Medytox's national growth, increasing the company's offerings, identifying businesses for potential acquisition and investment, and growing Medytox's management team. In addition, he will continue to raise capital for the company.
Medytox Solutions posts better income from operations of USD5.8m for 2014 quarter
M2 - Tue Aug 19, 11:09AM CDT
Clinical laboratory Medytox Solutions (OTC BB:MMMS) stated on Monday its income from operations of approximately USD5.8m for the three-month period ended 30 June 2014.
